Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma.
van Ravensteijn SG, Amir AL, Tauriello DVF, van Herpen CML, Boers-Sonderen MJ, Wesseling YJW, van Brussel AGC, Keizer DM, Verheul HMW, Bol KF. van Ravensteijn SG, et al. Among authors: boers sonderen mj. Clin Exp Immunol. 2024 Nov 30:uxae108. doi: 10.1093/cei/uxae108. Online ahead of print. Clin Exp Immunol. 2024. PMID: 39668127
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.
Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. Özkan A, et al. Among authors: boers sonderen mj. Eur J Cancer. 2024 Nov;212:115056. doi: 10.1016/j.ejca.2024.115056. Epub 2024 Sep 30. Eur J Cancer. 2024. PMID: 39368226 Free article.
Long-Term Survival in Patients With Advanced Melanoma.
van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot J W B JW, Hospers GAP, Kapiteijn E, Leeneman B, D P, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: boers sonderen mj. JAMA Netw Open. 2024 Aug 1;7(8):e2426641. doi: 10.1001/jamanetworkopen.2024.26641. JAMA Netw Open. 2024. PMID: 39141388 Free PMC article.
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.
Rauwerdink DJW, Not OV, de Meza M, Doorn RV, Hage JV, Eertwegh AJMVD, Haanen JB, Aarts MJB, Berkmortel FWPJVD, Blank CU, Boers-Sonderen MJ, Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Veldt AAMV, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Kapiteijn E. Rauwerdink DJW, et al. Among authors: boers sonderen mj. Cancers (Basel). 2024 Jul 26;16(15):2656. doi: 10.3390/cancers16152656. Cancers (Basel). 2024. PMID: 39123384 Free PMC article.
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.
van Duin IAJ, Schuiveling M, Ter Maat LS, Veta M, van Eijs MJM, Verheijden RJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, Hospers GAP, Labots M, de Groot JWB, Kapiteijn E, Piersma D, Vreugdenhil G, Westgeest H, Schrader AMR, van Diest PJ, Blokx WAM, Suijkerbuijk KPM. van Duin IAJ, et al. Among authors: boers sonderen mj. Immunooncol Technol. 2024 Jun 12;24:100714. doi: 10.1016/j.iotech.2024.100714. eCollection 2024 Dec. Immunooncol Technol. 2024. PMID: 39045171 Free PMC article.
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
Bloem M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, de Groot JB, Haanen JB, Hospers GAP, Kapiteijn EW, de Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. Bloem M, et al. Among authors: boers sonderen mj. Int J Cancer. 2024 Oct 15;155(8):1455-1465. doi: 10.1002/ijc.35060. Epub 2024 Jun 24. Int J Cancer. 2024. PMID: 38922879
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, van den Berkmortel FWPJ, Chatzidionysiou K, Llobell A, Barros M, Maria ATJ, Takeji A, García Morillo JS, Lidar M, van Eijs MJM, Blank CU, Aspeslagh S, Piersma D, Kapiteijn E, Labots M, Boers-Sonderen MJ, van der Veldt AAM, Haanen JBAG, May AM, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: boers sonderen mj. Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15. Eur J Cancer. 2024. PMID: 38905818 Free article.
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. Blank CU, et al. Among authors: boers sonderen mj. N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828984 Clinical Trial.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. Janssen JC, et al. Among authors: boers sonderen mj. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0. BMC Cancer. 2024. PMID: 38783238 Free PMC article.
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.
van der Hiel B, Aalbersberg EA, van den Eertwegh AJM, Fischer J, Boellaard R, de Vos FYFL, Boers-Sonderen MJ, Stokkel MPM, de Wit-van der Veen LJ, Haanen JBAG. van der Hiel B, et al. Among authors: boers sonderen mj. Clin Nucl Med. 2024 Aug 1;49(8):722-726. doi: 10.1097/RLU.0000000000005281. Epub 2024 May 14. Clin Nucl Med. 2024. PMID: 38768063
77 results